Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages
Summary: A quarter of all seasonal influenza cases are caused by type B influenza virus (IBV) that also dominates periodically. Here, we investigated a recombinant adenovirus vaccine carrying a synthetic HA2 representing the consensus sequence of all IBV hemagglutinins. The vaccine fully protected m...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c44338db000c4fca9f7baa27557288ba |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:c44338db000c4fca9f7baa27557288ba |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:c44338db000c4fca9f7baa27557288ba2021-11-20T05:09:59ZSynthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages2589-004210.1016/j.isci.2021.103328https://doaj.org/article/c44338db000c4fca9f7baa27557288ba2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2589004221012979https://doaj.org/toc/2589-0042Summary: A quarter of all seasonal influenza cases are caused by type B influenza virus (IBV) that also dominates periodically. Here, we investigated a recombinant adenovirus vaccine carrying a synthetic HA2 representing the consensus sequence of all IBV hemagglutinins. The vaccine fully protected mice from lethal challenges by IBV of both genetic lineages, demonstrating its breadth of protection. The protection was not mediated by neutralizing antibodies but robust antibody-dependent cellular cytotoxicity and cell-mediated immune responses. Complete protection of the animals required the entire codon-optimized HA2 sequence that elicited a balanced immune response, whereas truncated vaccines without either the fusion peptide or the transmembrane domain reduced the efficacy of protection. Finally, the vaccines did not demonstrate any sign of disease exacerbation following lung pathology and morbidity monitoring. Collectively, these data suggest that it could be worth further exploring this prototype universal vaccine because of its considerable efficacy, safety, and breadth of protection.Caroline GravelAbenaya MuralidharanAmparo DuranAdrian ZetnerAnnabelle PfeifleWanyue ZhangAnwar HashemLevi TammingAaron FarnsworthHugues LoembaWangxue ChenFlorian KrammerDavid SafronetzJingxin CaoLisheng WangSimon SauveMichael Rosu-MylesGary Van DomselaarXuguang LiElsevierarticleImmunologyimmune responseVirologyScienceQENiScience, Vol 24, Iss 11, Pp 103328- (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Immunology immune response Virology Science Q |
| spellingShingle |
Immunology immune response Virology Science Q Caroline Gravel Abenaya Muralidharan Amparo Duran Adrian Zetner Annabelle Pfeifle Wanyue Zhang Anwar Hashem Levi Tamming Aaron Farnsworth Hugues Loemba Wangxue Chen Florian Krammer David Safronetz Jingxin Cao Lisheng Wang Simon Sauve Michael Rosu-Myles Gary Van Domselaar Xuguang Li Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages |
| description |
Summary: A quarter of all seasonal influenza cases are caused by type B influenza virus (IBV) that also dominates periodically. Here, we investigated a recombinant adenovirus vaccine carrying a synthetic HA2 representing the consensus sequence of all IBV hemagglutinins. The vaccine fully protected mice from lethal challenges by IBV of both genetic lineages, demonstrating its breadth of protection. The protection was not mediated by neutralizing antibodies but robust antibody-dependent cellular cytotoxicity and cell-mediated immune responses. Complete protection of the animals required the entire codon-optimized HA2 sequence that elicited a balanced immune response, whereas truncated vaccines without either the fusion peptide or the transmembrane domain reduced the efficacy of protection. Finally, the vaccines did not demonstrate any sign of disease exacerbation following lung pathology and morbidity monitoring. Collectively, these data suggest that it could be worth further exploring this prototype universal vaccine because of its considerable efficacy, safety, and breadth of protection. |
| format |
article |
| author |
Caroline Gravel Abenaya Muralidharan Amparo Duran Adrian Zetner Annabelle Pfeifle Wanyue Zhang Anwar Hashem Levi Tamming Aaron Farnsworth Hugues Loemba Wangxue Chen Florian Krammer David Safronetz Jingxin Cao Lisheng Wang Simon Sauve Michael Rosu-Myles Gary Van Domselaar Xuguang Li |
| author_facet |
Caroline Gravel Abenaya Muralidharan Amparo Duran Adrian Zetner Annabelle Pfeifle Wanyue Zhang Anwar Hashem Levi Tamming Aaron Farnsworth Hugues Loemba Wangxue Chen Florian Krammer David Safronetz Jingxin Cao Lisheng Wang Simon Sauve Michael Rosu-Myles Gary Van Domselaar Xuguang Li |
| author_sort |
Caroline Gravel |
| title |
Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages |
| title_short |
Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages |
| title_full |
Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages |
| title_fullStr |
Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages |
| title_full_unstemmed |
Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages |
| title_sort |
synthetic vaccine affords full protection to mice against lethal challenge of influenza b virus of both genetic lineages |
| publisher |
Elsevier |
| publishDate |
2021 |
| url |
https://doaj.org/article/c44338db000c4fca9f7baa27557288ba |
| work_keys_str_mv |
AT carolinegravel syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT abenayamuralidharan syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT amparoduran syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT adrianzetner syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT annabellepfeifle syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT wanyuezhang syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT anwarhashem syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT levitamming syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT aaronfarnsworth syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT huguesloemba syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT wangxuechen syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT floriankrammer syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT davidsafronetz syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT jingxincao syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT lishengwang syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT simonsauve syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT michaelrosumyles syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT garyvandomselaar syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages AT xuguangli syntheticvaccineaffordsfullprotectiontomiceagainstlethalchallengeofinfluenzabvirusofbothgeneticlineages |
| _version_ |
1718419565603454976 |